Source: European Medicines Agency (EU) Revision Year: 2026 Publisher: Pharming Technologies B.V., Darwinweg 24, 2333 CR Leiden, The Netherlands
Joenja 70 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. Yellow, oval-shaped, biconvex, bevelled edge film-coated tablet debossed with "70" on one side and "LNB" on the other side, approximately 16 mm in length, 6.3 mm in width, and 6.0 mm in thickness. |
Each film-coated tablet contains leniolisib phosphate equivalent to 70 mg leniolisib.
Excipient with known effect:
Each film-coated tablet contains 241.16 mg of lactose monohydrate.
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Leniolisib inhibits PI3K-delta by blocking the active binding site of PI3K-delta. In cell-free isolated enzyme assays, leniolisib was selective for PI3K-delta over PI3K-alpha (28-fold), PI3K-beta (43-fold), and PI3K-gamma (257-fold), as well as the broader kinome. In cell-based assays, leniolisib reduced pAkt pathway activity and inhibited proliferation and activation of B and T cell subsets. |
| List of Excipients |
|---|
|
Tablet core: Lactose monohydrate Tablet film-coating: Hypromellose (E464) |
High density polyethylene bottles with aluminium induction seal and child resistant polypropylene screw cap.
Each pack contains 1 bottle with 60 tablets.
Pharming Technologies B.V., Darwinweg 24, 2333 CR Leiden, The Netherlands
EU/1/26/2034/001
| Drug | Countries | |
|---|---|---|
| JOENJA | United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.